Cat. No.: DAB-0012278
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu730 of human Mios protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MIOS |
| UniProt No. | Q9NXC5 |
| Gene ID | 54468 |
| Gene Description | The mTORC1 kinase complex plays a critical role in cell growth regulation. mTORC1 activity is modulated by energy levels, growth factors, and amino acids. Four related GTPases interact with raptor in mTORC1, which is necessary and sufficient for mTORC1 activation in response to amino acid signals. The GAP Activity Towards Rags complex interacts with Rag GTPases and is made up of a pair of protein subcomplexes. The GATOR1 subcomplex includes the proteins DEPDC5, Nprl2 and Nprl3, and is a RagA and RagB GTPase-activating protein that negatively regulates mTORC1 signaling. Conversely, the GATOR2 subcomplex is a positive regulator of mTORC1 signaling.The mammalian Mios protein contains six amino-terminal WD repeats and a carboxy terminal zinc finger-like domain. The homologous Drosophila missing oocyte protein is required for meiotic progression and oocyte cell fate maintenance during development. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
